VIDEO: Therapeutic options for hard-to-treat lymphoma

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify cperla@healio.com if there are concerns regarding accuracy of the transcription.

Peripheral T-cell lymphoma is a relatively rare disease in the Western hemisphere, but it's more common in Asian population. Out of non-Hodgkin lymphoma, probably 40 to 50% these lymphoma are T-cell or NK/T-cell related lymphoma. And unfortunately, this peripheral T-cell lymphoma is really hard to treat, and there is no acute therapy. The best therapy so far are still the chemotherapy such as CHOP, followed by autologous stem cell transplant or allogeneic stem cell transplant. And if you look at data in the last number of years, the long-term duration remission from a patient being transplanted are still probably have the best result compared with just chemotherapy alone. So at the ASH meeting in the last year or two, there's a number for trials, try to combine a novel agent, or new agent, in combination with a CHOP or C-H-O-P based therapy. One of the example is anti CD30 antibody conjugated drug, or ADC, and brentuximab. They show very promising result. The combination with CHP plus brentuximab as frontline therapy. And for a subset of the T-cell lymphoma, a very promising result. The one question remaining is, for these patient, or group of patient treated with this regimen, and should they get a bone marrow transplant for consolidation? And this is a remaining question. For patient who unfortunately relapse after frontline therapy, or another transplant candidate, the rest of therapy are primarily palliative. And there's a number of options, like a DNA hypomethylating agent being tested. One of the example is 5-azacytidine, being testing in for this disease. And another one is by a group of agent, very active HDAC inhibitors, the whole host of HDAC inhibitors. They are very active agent. And however, this palliation is not curative. The other class of drug we see very promising is PI 3-kinase inhibitors, and they also show some quite impressive activity as a single agent. Our trials are ongoing right now in combination with other active agent against the T-cell lymphoma.